These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 28314412)

  • 1. Development of LRRK2 Inhibitors for the Treatment of Parkinson's Disease.
    Christensen KV; Smith GP; Williamson DS
    Prog Med Chem; 2017; 56():37-80. PubMed ID: 28314412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).
    Galatsis P
    Expert Opin Ther Pat; 2017 Jun; 27(6):667-676. PubMed ID: 28117607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).
    Deng X; Choi HG; Buhrlage SJ; Gray NS
    Expert Opin Ther Pat; 2012 Dec; 22(12):1415-26. PubMed ID: 23126385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small-Molecule Inhibitors of LRRK2.
    Hatcher JM; Choi HG; Alessi DR; Gray NS
    Adv Neurobiol; 2017; 14():241-264. PubMed ID: 28353288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease.
    Domingos S; Duarte T; Saraiva L; Guedes RC; Moreira R
    Future Med Chem; 2019 Aug; 11(15):1953-1977. PubMed ID: 31517532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Pyrrolopyrimidines as LRRK2 Inhibitors for Treating Parkinson's Disease.
    De SK
    Curr Med Chem; 2024; 31(33):5477-5480. PubMed ID: 37605404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1).
    Williamson DS; Smith GP; Acheson-Dossang P; Bedford ST; Chell V; Chen IJ; Daechsel JCA; Daniels Z; David L; Dokurno P; Hentzer M; Herzig MC; Hubbard RE; Moore JD; Murray JB; Newland S; Ray SC; Shaw T; Surgenor AE; Terry L; Thirstrup K; Wang Y; Christensen KV
    J Med Chem; 2017 Nov; 60(21):8945-8962. PubMed ID: 29023112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rab29-dependent asymmetrical activation of leucine-rich repeat kinase 2.
    Zhu H; Tonelli F; Turk M; Prescott A; Alessi DR; Sun J
    Science; 2023 Dec; 382(6677):1404-1411. PubMed ID: 38127736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design.
    Ray S; Liu M
    Future Med Chem; 2012 Sep; 4(13):1701-13. PubMed ID: 22924508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Exposure to PFE-360 in the AAV-α-Synuclein Rat Model: Findings and Implications.
    Andersen MA; Sotty F; Jensen PH; Badolo L; Jeggo R; Smith GP; Christensen KV
    eNeuro; 2019; 6(6):. PubMed ID: 31685675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.
    Kramer T; Lo Monte F; Göring S; Okala Amombo GM; Schmidt B
    ACS Chem Neurosci; 2012 Mar; 3(3):151-60. PubMed ID: 22860184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Developments in LRRK2-Targeted Therapy for Parkinson's Disease.
    Zhao Y; Dzamko N
    Drugs; 2019 Jul; 79(10):1037-1051. PubMed ID: 31161537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LRRK2 and Parkinson's Disease: From Lack of Structure to Gain of Function.
    Blanca Ramírez M; Madero-Perez J; Rivero-Rios P; Martinez-Salvador M; Lara Ordonez AJ; Fernandez B; Fdez E; Hilfiker S
    Curr Protein Pept Sci; 2017; 18(7):677-686. PubMed ID: 26965688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition.
    Fell MJ; Mirescu C; Basu K; Cheewatrakoolpong B; DeMong DE; Ellis JM; Hyde LA; Lin Y; Markgraf CG; Mei H; Miller M; Poulet FM; Scott JD; Smith MD; Yin Z; Zhou X; Parker EM; Kennedy ME; Morrow JA
    J Pharmacol Exp Ther; 2015 Dec; 355(3):397-409. PubMed ID: 26407721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allosteric inhibition of LRRK2, where are we now.
    Soliman A; Cankara FN; Kortholt A
    Biochem Soc Trans; 2020 Oct; 48(5):2185-2194. PubMed ID: 33079169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
    Kethiri RR; Bakthavatchalam R
    Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of leucine-rich repeat kinase 2 (LRRK2): progress and promise for the treatment of Parkinson's disease.
    Gilligan PJ
    Curr Top Med Chem; 2015; 15(10):927-38. PubMed ID: 25832719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Update on the Development of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors: A Promising Target for the Treatment of Parkinson's Disease.
    Patel A; Patel S; Mehta M; Patel Y; Langaliya D; Bhalodiya S; Bambharoliya T
    Med Chem; 2022; 18(7):757-771. PubMed ID: 35168510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decoding Inhibitor Egression from Wild-Type and G2019S Mutant LRRK2 Kinase: Insights into Unbinding Mechanisms for Precision Drug Design in Parkinson's Disease.
    Naskar A; Roy RK; Srivastava D; Patra N
    J Phys Chem B; 2024 Jul; 128(28):6657-6669. PubMed ID: 38822803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting LRRK2 in Parkinson's disease: an update on recent developments.
    Chan SL; Tan EK
    Expert Opin Ther Targets; 2017 Jun; 21(6):601-610. PubMed ID: 28443359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.